Skip to content
(845) 826-1651
Get Assessment
Titan Group_Logo_White_Cropped
(347) 723-8019
Get Assessment
    Case Study

    Transforming DEA Compliance Across CVP Veterinary Hospitals

    Download a Copy
    shutterstock_1361660537

    Background

    In 2024, Titan Group conducted comprehensive DEA compliance audits across seventeen Community Veterinary Partners (CVP) hospitals. The objective: to assess adherence to the Controlled Substances Act (21 U.S.C. § 801 et seq.) and its implementing regulations (21 CFR Parts 1301–1307). Findings revealed systemic vulnerabilities in recordkeeping, inventory reconciliation, and procedural oversight—issues that, while not evidencing diversion, represented material non-compliance with DEA requirements. Titan Group was engaged to correct these deficiencies and rebuild CVP’s compliance infrastructure from the ground up.

    Challenges Identified

    TITAN Group Lifecycle Nurture Emails_Email 1 - Resources Icon v1
    Incomplete or missing controlled-substance records
    TITAN Group Lifecycle Nurture Emails_Email 1 - Resources Icon v2
    Missing or unverified DEA Form 222/CSOS documentation
    TITAN Group Lifecycle Nurture Emails_Email 1 - Chaos to Control Icon v1
    Lack of biennial inventory records and perpetual tracking
    TITAN Group Lifecycle Nurture Emails_Email 3 - Checkmark Icon v2 (1)
    Improper storage and access control for Schedule II/III drugs
    TITAN Group Lifecycle Nurture Emails_Email 1 - Resources Icon v2
    Missing Power of Attorney documentation

    • Standardized DEA Recordkeeping Protocols across all CVP hospitals.

    • SageComply™ Implementation – centralized DEA compliance platform for ordering, inventory, and reconciliation.

    • Registrant Education & Certification to ensure ongoing staff competency.

    • Quarterly Internal Audits to maintain verifiable, auditable compliance.

    • Corporate Oversight Program ensuring enterprise-wide control and transparency.

    Titan Group’s Solution

    Results & Impact

    Metric

    Before

    After

    Average Violations per Facility

    10–12

    0–1

    Theoretical Exposure

    $3.4–$5M

    $0

    DEA Enforcement Outcome

    Pending

    LOA / CAP Only

    Corporate Oversight

    Inconsistent

    Centralized via SageComply™

     

    shutterstock_2268378539-iso

    Conclusion

    By partnering with Titan Group, CVP transformed from a network at regulatory risk to a model of compliance excellence. The company’s commitment to transparency, documentation, and proactive control positioned it as a cooperative DEA registrant—minimizing exposure while strengthening operational integrity.

     

    Titan Group: From Risk to Regulatory Resilience

    info@titangroupdea.com

     Download a Copy of the Case Study